2023 has brought with it some big-ticket patent expiries on the Indian market.
Even as twists and turns around the patent battle pertaining to Novartis’s heart-failure therapy Entresto (sacubitril/valsartan) continue to play...
Ibrance Generics Arrive In India, Patient Programs Add Free Drug Component
Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?
